THU0192 INFORMING PATIENTS ABOUT METHOTREXATE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS WITH PATIENTS IN THE UNITED KINGDOM -A SURVEY OF RHEUMATOLOGISTS' STRATEGIES
Background: Rheumatologists are the primary prescribers of methotrexate (MTX) for the treatment of rheumatoid arthritis (RA) in the United Kingdom (UK), however rheumatologists' views on their clinical practices are largely unknown. The authors conducted a qualitative study that highlighted a number of factors that contributed to their ability to discuss and commence MTX, which included how emotionally and cognitively prepared patients were to discuss treatments. The aim of this study was to further explore these themes with an online survey. Objectives: The aims of this study were:1)To establish the views of rheumatologists about MTX for the treatment of rheumatoid arthritis (RA), 2)To examine if rheumatologists' views influenced discussing or commencing MTX during the initial consultation. Methods: An online survey was designed and subsequently refined based on interviews with rheumatologists in the UK. The survey asked rheumatologists about their clinical setting, and their views and practices with respect to treating RA with MTX. Rheumatologists were asked how often specific pieces of MTX information were discussed during a consultation to commence MTX (5=Always to 1=never). They were also asked to identify the barriers to discussing these issues. The questionnaire included a factorial survey ie. two patient vignettes where we manipulated the following factors; male/female, emotionally prepared/unprepared and no/negative prior knowledge. Rheumatologists could select "information overload" as a barrier to communication with the patient. Random mixed effects models tested if these patient factors and information overload associated with 1) commencing and 2) discussing MTX. Results: Ninety-six rheumatologists seeing approximately eight (IQR:5-12) new patients a week with 15±7 years of experience completed the survey. Rheumatologists reported they often/always discussed ten (IQR 8-11) pieces of information during a consultation (Fig 1A) , and information overload was identified as a communication barrier (48%); 52% of rheumatologists expected the nurse to discuss MTX therapy (Fig 1B) . Sixty rheumatologists completed one, and 56 rheumatologists two vignettes (n=116). The vignette conditions and information overload significantly associated with "Commencing MTX" (X 2 =53.85, p <.0001, R 2 =.21) and discussing MTX (X 2 =30.9, p =.002, R 2 =.19). Gender* emotional preparedness (β=-4.27, 95% CI:-7.33,-1.21), and information overload*emotional preparedness (β=-3.03, 95% CI:-5.24, -.82) associated with MTX commencement, whilst only gender*emotional preparedness with discussing MTX (β=-3.86, 95% CI:-6.82, -.90).
Conclusions:
Currently UK rheumatologists convey a large amount of information to patients during early consultations. Almost half of rheumatologists identified the need to communicate large amounts of information in clinical consultations as a barrier to discussing MTX therapy. These data reflect the challenge clinicians face in trying to execute effective shared decision-making practices. Strategies to address patients' emotional responses to their diagnosis and being overloaded with MTX information are needed. Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Objectives: To assess the efficacy and safety of tofacitinib after temporary discontinuation and reinitiation of therapy in RA patients (pts). Methods: Data were collected from a randomised, parallel-group (grp), controlled, open label, vaccine sub-study in RA pts participating in a long-term extension (LTE) study (NCT00413699). Pts were ≥18 years of age with active RA and had received tofacitinib 10 mg BID for ≥3 months. The sub-study included 2 treatment (tx) grps: "continuous tx" (tofacitinib 10 mg twice daily [BID] as monotherapy or with methotrexate [MTX]) and "interrupted tx" (tofacitinib withdrawn for 2 weeks post-randomisation [Day 1-Day 15; Visits 1-3], then tofacitinib 10 mg BID reinitiated as monotherapy or with MTX at Visit 3); randomisation was stratified by MTX use. Pneumococcal and influenza vaccines were administered to all pts on Day 8 (Visit 2; vaccine titers reported previously 1 ). Blood samples were taken on Days 8, 15 (Visit 3) and 43 (Visit 4). Efficacy endpoints included change from baseline in C-reactive protein (CRP), Health Assessment Questionnaire Disability Index (HAQ-DI) and Disease Activity Score in 28 joints, erythrocyte sedimentation rate (DAS28-4[ESR]) at each visit. A mixed-effects model with repeated measures was used to evaluate treatment effect at each visit. Analyses for efficacy were exploratory, with no multiplicity adjustment for comparisons. Results: Of the 199 pts in this analysis (continuous, n=100; interrupted, n=99), 117 received concomitant MTX. At LTE study baseline (BL) in the continuous and interrupted grps, respectively: 81.8/83.8% of pts were white, 84.8/86.9% were female and mean age was 55.0/53.9 years. BL (Day 1) values for CRP, HAQ-DI and DAS28-4(ESR) were generally similar between groups. At Day 8, mean CRP and DAS28-4(ESR) significantly increased from BL for interrupted vs continuous tx; HAQ-DI values were similar between grps (Figure) . As expected at Day 15, mean CRP, HAQ-DI and DAS28-4(ESR) significantly increased from BL for interrupted vs continuous tx. After tofacitinib reinitiation for 28 days (Day 43), changes in CRP, HAQ-DI and DAS28-4(ESR) were similar between grps and approached BL levels. Adverse events (AEs) were experienced by 35.4% and 49.5% of pts receiving interrupted and continuous tx, respectively. The most frequent treatment-emergent AEs were bronchitis and upper respiratory tract infection (each AE: 6 pts) and vaccination-related immunisation reaction, myalgia and rash (each AE: 5 pts). Serious AEs occurred in 3 pts (3%) in each grp. In total, 1 pt (1%), in the interrupted tx grp, discontinued due to a study-drug related AE; no pts discontinued due to disease flare.
Efficacy of tofacitinib 10 mg BID can be reestablished following loss of efficacy during temporary (2 weeks) tx discontinuation in pts with RA. Pts receiving continuous tx maintained efficacy throughout the study. Further investigations are required.
References:
[1] Winthrop KL et al. Ann Rheum Dis 2016; 75: 687-695. 
